Several targeting approaches are in development. BCMA is preferentially expressed on plasma cells and other mature B cells in blood 5. These cells originate with B-lymphocyte progenitors that ...

B-cell maturation antigen, or BCMA, is selectively expressed when plasma cells differentiate. It is almost absent on memory and naive B cells. The maintenance of long-lived plasma cells involves ...

With the undeniable excitement in the BCMA field over the past few months, the BCMA Targeted Therapies Summit returns to the space to equip you with the knowledge and connections to revolutionize ...

Built with thought leaders from Seattle Genetics, Precision Biosciences and Kite Pharma, the inaugural industry-focused BCMA Targeted Therapies Summit will share the field’s cutting-edge and ...

ESO-T01 is the first in vivo BCMA CAR-T candidate to be dosed in a human clinical trial, and has been developed by EsoBiotec using its third-generation immune-shielded cell specific lentiviral ...

BCMA, and CD3, developed independently by Simcere Zaiming using their T-cell engager polyspecific antibody technology platform. This molecule features a low affinity/high target-activating CD3 ...

BCMA, and CD3, developed independently by Simcere Zaiming using their T-cell engager polyspecific antibody technology platform. This molecule features a low affinity/high target-activating CD3 ...